# Novartis Z Score

NVSEF
Stock

## USD 83.750.951.12%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Additionally, see Novartis Piotroski F Score and Novartis Valuation analysis.
 Novartis

## Novartis Z Score Analysis

Novartis' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 Z Score = Sum Of 5 Factors
More About Z Score | All Equity Analysis

### Current Novartis Z Score

3.6
Most of Novartis' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis Ag Basl is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 First Factor = 1.2 * ( Working Capital / Total Assets )
 Second Factor = 1.4 * ( Retained Earnings / Total Assets )
 Thrid Factor = 3.3 * ( EBITAD / Total Assets )
 Fouth Factor = 0.6 * ( Market Value of Equity / Total Liabilities )
 Fifth Factor = 0.99 * ( Revenue / Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
 Compare to competition Predict Novartis
Based on the company's disclosures, Novartis Ag Basl has a Z Score of 3.6. This is 46.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturersâ€”General industry. The z score for all United States stocks is 58.72% higher than that of the company.

## Novartis Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.
Novartis is currently under evaluation in z score category among related companies.

## Novartis ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novartis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novartis' managers, analysts, and investors.
 Environment Score Governance Score Social Score

## Novartis Fundamentals

 Return On Equity 39.23 % Return On Asset 6.72 % Profit Margin 43.54 % Operating Margin 25.14 % Current Valuation 203.68 B Shares Outstanding 2.24 B Shares Owned by Insiders 3.74 % Shares Owned by Institutions 34.55 % Price to Earning 19.57 X Price to Book 3.34 X Price to Sales 3.60 X Revenue 52.79 B Gross Profit 37.44 B EBITDA 18.43 B Net Income 22.98 B Cash and Equivalents 19.64 B Cash per Share 9.00 X Total Debt 31.09 B Debt to Equity 0.49 % Current Ratio 1.38 X Book Value Per Share 25.38 X Cash Flow from Operations 14.21 B Earnings Per Share 4.33 X Number of Employees 108 K Beta 0.5 Market Capitalization 189.8 B Total Asset 134.01 B Working Capital 1.28 B Current Asset 25.88 B Current Liabilities 24.6 B Z Score 3.6 Five Year Return 3.29 % Last Dividend Paid 3.35

## About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis Ag Basl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis Ag Basl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 108000 people.

## Novartis Investors Sentiment

The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Novartis' public news can be used to forecast risks associated with investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis Ag Basl. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimate score, the more favorable is the investor's outlook on Novartis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Novartis Ag Basl using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

## Build Optimal Portfolios

### Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Novartis Piotroski F Score and Novartis Valuation analysis. Note that the Novartis Ag Basl information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

## Complementary Tools for Novartis OTC Stock analysis

When running Novartis Ag Basl price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
 Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk Go Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account Go Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments Go Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios Go Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios Go Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device Go Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance Go Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets Go
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
 Quarterly Earnings Growth YOY-0.4 Market Capitalization186.6 B Quarterly Revenue Growth YOY-0.016 Return On Assets0.0672 Return On Equity0.39
The market value of Novartis Ag Basl is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine Novartis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.